299 related articles for article (PubMed ID: 20579215)
21. A nontumorigenic variant of FGF19 treats cholestatic liver diseases.
Luo J; Ko B; Elliott M; Zhou M; Lindhout DA; Phung V; To C; Learned RM; Tian H; DePaoli AM; Ling L
Sci Transl Med; 2014 Jul; 6(247):247ra100. PubMed ID: 25080475
[TBL] [Abstract][Full Text] [Related]
22. Use of ursodeoxycholic acid in patients with liver disease.
Angulo P
Curr Gastroenterol Rep; 2002 Feb; 4(1):37-44. PubMed ID: 11825540
[TBL] [Abstract][Full Text] [Related]
23. [Ursodeoxycholic acid in the treatment of chronic cholestatic liver disease. Documented delay in disease progress inspires hope].
Olsson R
Lakartidningen; 2002 Mar; 99(12):1325-30. PubMed ID: 11998165
[TBL] [Abstract][Full Text] [Related]
24. [Cholestatic liver disease in children].
Jankowska I; Pawłowska J; Swiatkowska E; Rujner J; Socha J
Przegl Epidemiol; 2002; 56 Suppl 5():16-21. PubMed ID: 15553067
[TBL] [Abstract][Full Text] [Related]
25. Ursodeoxycholic acid therapy in hepatobiliary disease.
Kowdley KV
Am J Med; 2000 Apr; 108(6):481-6. PubMed ID: 10781781
[TBL] [Abstract][Full Text] [Related]
26. New Insights on Intrahepatic Cholestasis of Pregnancy.
Floreani A; Gervasi MT
Clin Liver Dis; 2016 Feb; 20(1):177-89. PubMed ID: 26593298
[TBL] [Abstract][Full Text] [Related]
27. Failure of ursodeoxycholic acid to prevent a cholestatic episode in a patient with benign recurrent intrahepatic cholestasis: a study of bile acid metabolism.
Crosignani A; Podda M; Bertolini E; Battezzati PM; Zuin M; Setchell KD
Hepatology; 1991 Jun; 13(6):1076-83. PubMed ID: 2050325
[TBL] [Abstract][Full Text] [Related]
28. Bile acid conjugation in early stage cholestatic liver disease before and during treatment with ursodeoxycholic acid.
Fracchia M; Setchell KD; Crosignani A; Podda M; O'Connell N; Ferraris R; Hofmann AF; Galatola G
Clin Chim Acta; 1996 Apr; 248(2):175-85. PubMed ID: 8740581
[TBL] [Abstract][Full Text] [Related]
29. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
Poupon R
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S3-12. PubMed ID: 23141891
[TBL] [Abstract][Full Text] [Related]
30. New therapeutical indications of ursodeoxycholic acid.
Copaci I; Micu L; Iliescu L; Voiculescu M
Rom J Gastroenterol; 2005 Sep; 14(3):259-66. PubMed ID: 16200237
[TBL] [Abstract][Full Text] [Related]
31. [Ursodeoxycholic acid: history and clinical implications].
Beuers U; Trampert DC
Ned Tijdschr Geneeskd; 2022 Sep; 166():. PubMed ID: 36300467
[TBL] [Abstract][Full Text] [Related]
32. Therapy of Primary Biliary Cirrhosis: Novel Approaches for Patients with Suboptimal Response to Ursodeoxycholic Acid.
Parés A
Dig Dis; 2015; 33 Suppl 2():125-33. PubMed ID: 26642350
[TBL] [Abstract][Full Text] [Related]
33. Delta 4-3-oxosteroid 5 beta-reductase deficiency: failure of ursodeoxycholic acid treatment and response to chenodeoxycholic acid plus cholic acid.
Clayton PT; Mills KA; Johnson AW; Barabino A; Marazzi MG
Gut; 1996 Apr; 38(4):623-8. PubMed ID: 8707100
[TBL] [Abstract][Full Text] [Related]
34. Use of ursodeoxycholic acid in liver diseases.
Kumar D; Tandon RK
J Gastroenterol Hepatol; 2001 Jan; 16(1):3-14. PubMed ID: 11206313
[TBL] [Abstract][Full Text] [Related]
35. An insight into primary biliary cholangitis and its recent advances in treatment: semi-synthetic analogs to combat ursodeoxycholic-acid resistance.
Sahu R; Mishra R; Majee C
Expert Rev Gastroenterol Hepatol; 2020 Oct; 14(10):985-998. PubMed ID: 32674617
[TBL] [Abstract][Full Text] [Related]
36. Molecular mechanisms of cholestasis.
Zollner G; Trauner M
Wien Med Wochenschr; 2006 Jul; 156(13-14):380-5. PubMed ID: 16937039
[TBL] [Abstract][Full Text] [Related]
37. Pathogenesis of cholestatic liver disease and therapeutic approaches.
Hirschfield GM; Heathcote EJ; Gershwin ME
Gastroenterology; 2010 Nov; 139(5):1481-96. PubMed ID: 20849855
[TBL] [Abstract][Full Text] [Related]
38. Cell Death and microRNAs in Cholestatic Liver Diseases: Update on Potential Therapeutic Applications.
Castro RE; Rodrigues CMP
Curr Drug Targets; 2017; 18(8):921-931. PubMed ID: 26477457
[TBL] [Abstract][Full Text] [Related]
39. Investigational drugs in phase II clinical trials for primary biliary cholangitis.
Silveira MG; Lindor KD
Expert Opin Investig Drugs; 2017 Oct; 26(10):1115-1121. PubMed ID: 28836457
[TBL] [Abstract][Full Text] [Related]
40. Geoepidemiology and changing mortality in primary biliary cholangitis.
Floreani A; Tanaka A; Bowlus C; Gershwin ME
J Gastroenterol; 2017 Jun; 52(6):655-662. PubMed ID: 28365879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
